- About Us
- What We Do
- Sector Expertise
- Contact Us
Corporate advisors, Asia and Australia.
AFG Venture Group provides corporate advisory and consultancy services through its offices in Australia, South East Asia and India and its networks around the world.
We work with Boards and Chief Executives to determine the optimal business model for commercialising a new technology including market entry, funding, licensing and partnering strategies, identifying counterparties for both local businesses expanding on or off-shore and multinationals seeking acquisition targets by way of entry to the Asia-Pac region. This requires a good understanding of the technology, the market, the people and the intellectual property (considerations which are used to determine the size of the market opportunity, the risks and how best to mitigate them); and an informed and dispassionate view of the likely structure and size of a deal based on comparables, cashflows (historical and forecast) and market intelligence.
We understand the needs of emerging technology companies in regards to appropriate governance, project and performance management to optimise research dollars and allocate resources efficiently and effectively, and work with the t team to understand goals and issues and agree opportunities, priorities, actions and performance targets. Our advice is built on over twenty years consulting to public and private organizations ,universities, research institutes and R&D businesses in Australia and overseas and can be summarised under four main areas:
1. Mergers & Acquisitions , Capital Raising & Technology Commercialisation
Life Sciences and technology businesses face challenges associated with determining the optimal commercialisation strategy, accessing the resources needed to execute the strategy and implementing disciplines to deliver to agreed milestones. We can meet these challenges in a number of ways:
2. Strategic Planning, Business Transformation and Growth
3. Medical Research Reviews
Undertaking scientific and medical research either as a primary or secondary activity face challenges around:
We have extensive experience in optimizing medical research portfolio management and effectiveness in organisations undertaking both applied and medical research..
Apr 19 2013 — CEDA report – ‘Healthcare: Reform or ration’
May 16 2011 — Cell Therapy Commercialisation
May 16 2011 — 2011 – Another Big Year for Australian Biotech
Christine Cussen is a business builder with over 20 years experience as an MD & CEO in the healthcare and life sciences sectors .She is passionate about growing businesses, customers, people and the bottom line.
Christine has been privileged to have worked in Australia, North America, Europe & Asian territories, with both global multi-nationals and entrepreneurial ASX listed start-ups organizations in very diverse sectors including pharmaceuticals, biotechnology, industrials, government and innovation.[more...]
Jan 16 2017 — Portfolio Investment in Asia 2017
Jan 16 2017 — COMPARATIVE OPERATING COSTS IN ASIA 2016
Jun 16 2016 — Emerging Markets As Investment Targets
Jun 16 2016 — Investing In An Emerging Market In Asia